|
 Intas Pharmaceuticals has entered into an exclusive agreement with IntegriMedical, the technology leader behind India’s first needle-free injection system (N-FIS), to introduce this revolutionary technology for use in IVF and gynaecology treatments across India.
This, the company said marks a significant milestone in IVF and women’s health. Securing exclusivity for a first-of-its-kind needle-free injector transforms both the delivery and experience of treatment, placing patient comfort and confidence at the forefront of care.
Through this agreement, Intas becomes the first and only company in India to offer IVF and gynaecology therapies with needle-free injections, setting a new benchmark for patient-centric innovative drug delivery system. The collaboration represents a decisive step in transforming how reproductive care is delivered.
With IntegriMedical’s proprietary drug-delivery technology, Intas aims to reduce injection-related discomfort and anxiety while enhancing compliance and patient satisfaction. Under the agreement, Intas, in collaboration with IntegriMedical, will streamline deployment of needle-free injections across IVF clinics and gynaecology centres nationwide.
India represents one of the fastest-growing IVF markets globally. Reportedly, the current number is around 300,000 to 350,000 cycles per year, with projections suggesting this could increase to 500,000 to 600,000 cycles by 2027. At scale, this results in several million injections administered every year as part of IVF treatment in India alone. By integrating needle-free injection technology into IVF treatment pathways, the collaboration is expected to improve the treatment experience for hundreds of thousands of women annually, particularly by reducing injection-related pain, anxiety, and treatment fatigue.
It’s incredibly rewarding to see our vision come to life through this groundbreaking collaboration with Intas. For IntegriMedical, this is more than a technical achievement, it’s about making treatments less intimidating, more comfortable, and truly humane. Congratulations to the Intas team for leading this country-first initiative in IVF and gynaecology. Together, we are taking a meaningful step forward in putting patients at the heart of care,” said Sarvesh Mutha, managing director, IntegriMedical.
Durga P Satapathy, executive vice president, Intas, said, “This initiative is about more than introducing a new technology; it’s about changing how patients experience care. IVF and gynaecology treatments can be demanding, and our goal is to make every step easier, more reassuring, and more dignified. Collaborations like this show what’s possible when innovation is truly focused on people. By leading such patient-centric advancements, we are setting a new benchmark for care in the country.”
N-FIS delivers medication through a high-pressure jet stream mechanism in a consistent, predictable, spray-like pattern. Medication is administered through a fine micro-orifice in the skin, enabling effective delivery without the use of needles. Unlike traditional needle-based injections, this approach minimizes tissue trauma, avoids medication pooling, and reduces the risk of cross-contamination.
|